A new collaborative model linking companies, academia and government should save the pharmaceutical industry millions and help smaller firms in Britain reorientate to supply the pharma manufacturing of tomorrow.
Had you asked GlaxoSmithKline, AstraZeneca and Novartis a few years ago to cuddle up, share manufacturing processes and collaborate on new ones, you might have been given one of their stronger tablets and told to lie down. But decades of inertia in reforming the manufacturing supply chain and huge amounts of wasted stock have caused…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
